By concurrently disengaging the CXCR4/CXCL12-mediated immunosuppressive microenvironment and promoting tumour-specific immunity, this dual-action strategy provides a novel and synergistic approach to target drug resistance in triple-negative breast cancer [100]. The gene discussed is CXCL12; the disease is triple-negative breast carcinoma.